Nuria Malats

List of Publications by Year in Descending Order

228 papers	12,501 citations	66 h-index	105 g-index
239 ext. papers	14,875 ext. citations	8.2 avg, IF	5.46 L-index

#	Paper	IF	Citations
228	A faecal microbiota signature with high specificity for pancreatic cancer.. *Gut*, **2022**,	19.2	5
227	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies.. *Environmental Health Perspectives*, **2022**, 130, 57006	8.4	1
226	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. *Gut*, **2021**, 70, 319-329	19.2	16
225	Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals Negativity and a Longer Overall Survival. *Cancers*, **2021**, 13,	6.6	1
224	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. *Nature Communications*, **2021**, 12, 2301	17.4	24
223	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. *Carcinogenesis*, **2021**, 42, 1037-1045	4.6	2
222	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. *American Journal of Clinical Nutrition*, **2021**, 114, 1408-1417	7	2
221	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. *Cancers*, **2021**, 13,	6.6	4
220	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. *Genome Medicine*, **2021**, 13, 15	14.4	6
219	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. *Cancer Research*, **2021**, 81, 3134-3143	10.1	2
218	Association of patients's sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. *World Journal of Urology*, **2021**, 39, 3337-3344	4	3
217	Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. *Actas Urológicas Españolas (English Edition)*, **2021**, 45, 473-478	0.1	
216	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. *Frontiers in Genetics*, **2021**, 12, 693933	4.5	2
215	UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. *United European Gastroenterology Journal*, **2021**, 9, 860	5.3	5
214	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. *European Urology Oncology*, **2021**, 5, 70-70	6.7	0
213	A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. *American Journal of Human Genetics*, **2021**, 108, 1852-1865	11	1
212	Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features. *Frontiers in Immunology*, **2021**, 12, 730746	8.4	1

#	Reference	IF	Cit
211	Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. *International Journal of Cancer*, **2021**, 148, 2048-2058	7.5	4
210	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. *Biomedicine Hub*, **2020**, 5, 182-223	1.3	6
209	DNA Methylation-Derived Immune Cell Profiles, CpG Markers of Inflammation, and Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1577-1585	4	7
208	Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1784-1791	4	4
207	Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. *Cancers*, **2020**, 12,	6.6	7
206	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. *Cancer Research*, **2020**, 80, 4004-4013	10.1	1
205	A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. *EBioMedicine*, **2020**, 53, 102675	8.8	16
204	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1009-1018	4	15
203	Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1501-1508	4	9
202	A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. *PLoS Medicine*, **2020**, 17, e1003489	11.6	5
201	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 1003-1012	9.7	25
200	Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. *Environment International*, **2020**, 135, 105346	12.9	8
199	Bratislava Statement: consensus recommendations for improving pancreatic cancer care. *ESMO Open*, **2020**, 5, e001051	6	2
198	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2735-2739	4	2
197	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. *European Urology*, **2020**, 77, 420-433	10.2	309
196	Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. *Environmental and Molecular Mutagenesis*, **2019**, 60, 693-703	3.2	8
195	Challenges in the Integration of Omics and Non-Omics Data. *Genes*, **2019**, 10,	4.2	46
194	Author's reply to: Air pollution and incident bladder cancer: A risk assessment. *International Journal of Cancer*, **2019**, 145, 3178	7.5	

193	CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. *Bladder Cancer*, **2019**, 5, 159-169	1	2
192	Perspectives on Data Integration in Human Complex Disease Analysis **2019**, 1826-1866		
191	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. *International Journal of Cancer*, **2019**, 144, 1540-1549	7.5	4
190	Ambient air pollution and incident bladder cancer risk: Updated analysis of the Spanish Bladder Cancer Study. *International Journal of Cancer*, **2019**, 145, 894-900	7.5	14
189	Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer. *Proteomics - Clinical Applications*, **2019**, 13, e1800148	3.1	4
188	Reply to Mosaic loss of chromosome Y in leukocytes matters. *Nature Genetics*, **2019**, 51, 7-9	36.3	6
187	Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. *Gut*, **2019**, 68, 130-139	19.2	86
186	Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. *International Journal of Epidemiology*, **2018**, 47, 473-483	7.8	20
185	Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. *Nature*, **2018**, 554, 533-537	50.4	57
184	Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. *Clinical Cancer Research*, **2018**, 24, 1586-1593	12.9	48
183	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. *Nature Communications*, **2018**, 9, 556	17.4	103
182	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World Journal of Urology*, **2018**, 36, 1621-1627	4	18
181	Genome-wide association study identifies inversion in the locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. *Gut*, **2018**, 67, 1855-1863	19.2	54
180	Asthma status is associated with decreased risk of aggressive urothelial bladder cancer. *International Journal of Cancer*, **2018**, 142, 470-476	7.5	8
179	Bladder Cancer Genetic Susceptibility. A Systematic Review. *Bladder Cancer*, **2018**, 4, 215-226	1	16
178	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. *World Journal of Urology*, **2018**, 36, 1775-1781	4	8
177	Genetic Testing, Genetic Variation, and Genetic Susceptibility **2018**, 629-649		
176	Response to: Variation of the age at onset of pancreatic cancer according to tobacco smoking and family history. *International Journal of Epidemiology*, **2018**, 47, 1358-1359	7.8	2

175	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. *Gut*, **2017**, 66, 314-322	19.2	37
174	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. *Gut*, **2017**, 66, 1665-1676	19.2	125
173	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. *Annals of Oncology*, **2017**, 28, 1618-1624	10.3	15
172	FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. *Journal of Urology*, **2017**, 197, 1410-1418	2.5	53
171	Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. *Carcinogenesis*, **2017**, 38, 1167-1179	4.6	9
170	Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. *European Urology*, **2017**, 72, 461-469	10.2	51
169	Health Literacy: Read All about It *Biomedicine Hub*, **2017**, 2, 44-47	1.3	0
168	Genomics in Primary and Secondary Prevention of Pancreatic Cancer. *Public Health Genomics*, **2017**, 20, 92-99	1.9	2
167	Cancer Genomics and Public Health. *Public Health Genomics*, **2017**, 20, 67-69	1.9	2
166	Integrative eQTL analysis of tumor and host omics data in individuals with bladder cancer. *Genetic Epidemiology*, **2017**, 41, 567-573	2.6	1
165	DoriTool: A Bioinformatics Integrative Tool for Post-Association Functional Annotation. *Public Health Genomics*, **2017**, 20, 126-135	1.9	3
164	Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy. *Journal of Urology*, **2017**, 197, 590-595	2.5	76
163	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 484.e19-484.e25	2.8	39
162	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. *Nature Genetics*, **2016**, 48, 1330-1338	36.3	104
161	Toward the integration of Omics data in epidemiological studies: still a "long and winding road". *Genetic Epidemiology*, **2016**, 40, 558-569	2.6	15
160	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. *Nature Communications*, **2016**, 7, 11843	17.4	59
159	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. *Cancer Cell*, **2016**, 30, 27-42	24.3	325
158	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. *Human Molecular Genetics*, **2016**, 25, 1203-14	5.6	20

157	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. *PLoS Genetics*, **2016**, 12, e1006493	6	67
156	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget*, **2016**, 7, 66328-66343	3.3	66
155	Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. *BMC Cancer*, **2016**, 16, 351	4.8	7
154	Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1144-50	4	7
153	Mosaic loss of chromosome Y is associated with common variation near TCL1A. *Nature Genetics*, **2016**, 48, 563-8	36.3	87
152	The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. *BJU International*, **2016**, 118, 44-52	5.6	72
151	Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2015**, 21, 3512-21	12.9	120
150	Epidemiology of bladder cancer. *Hematology/Oncology Clinics of North America*, **2015**, 29, 177-89, vii	3.1	109
149	Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	23
148	PanGen-Fam: Spanish registry of hereditary pancreatic cancer. *European Journal of Cancer*, **2015**, 51, 1911-7	7.5	32
147	Framework for the Integration of Genomics, Epigenomics and Transcriptomics in Complex Diseases. *Human Heredity*, **2015**, 79, 124-36	1.1	19
146	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. *European Urology*, **2015**, 67, 74-82	10.2	149
145	Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. *BMC Cancer*, **2015**, 15, 797	4.8	116
144	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *Journal of the National Cancer Institute*, **2015**, 107, djv279	9.7	107
143	Vitamin D metabolic pathway genes and pancreatic cancer risk. *PLoS ONE*, **2015**, 10, e0117574	3.7	26
142	Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer. *PLoS Genetics*, **2015**, 11, e1005689	6	49
141	A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. *International Journal of Proteomics*, **2015**, 2015, 587250		20
140	Characterization of large structural genetic mosaicism in human autosomes. *American Journal of Human Genetics*, **2015**, 96, 487-97	11	77

| 139 | Nitrate in drinking water and bladder cancer risk in Spain. *Environmental Research*, **2015**, 137, 299-307 | 7.9 | 62 |

| 138 | Perspectives on Data Integration in Human Complex Disease Analysis. *Advances in Bioinformatics and Biomedical Engineering Book Series*, **2015**, 284-322 | 0.4 | 1 |

| 137 | Genome-wide interaction study of smoking and bladder cancer risk. *Carcinogenesis*, **2014**, 35, 1737-44 | 4.6 | 33 |

| 136 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46 | 5.6 | 28 |

| 135 | Genome-wide association study identifies multiple loci associated with bladder cancer risk. *Human Molecular Genetics*, **2014**, 23, 1387-98 | 5.6 | 101 |

| 134 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genetic Epidemiology*, **2014**, 38, 84-93 | 2.6 | 24 |

| 133 | The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. *Cancer Research*, **2014**, 74, 5808-18 | 10.1 | 19 |

| 132 | Whole genome prediction of bladder cancer risk with the Bayesian LASSO. *Genetic Epidemiology*, **2014**, 38, 467-76 | 2.6 | 10 |

| 131 | Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nature Genetics*, **2014**, 46, 994-1000 | 36.3 | 226 |

| 130 | Inflammatory biomarkers and bladder cancer prognosis: a systematic review. *European Urology*, **2014**, 66, 1078-91 | 10.2 | 66 |

| 129 | Next generation modeling in GWAS: comparing different genetic architectures. *Human Genetics*, **2014**, 133, 1235-53 | 6.3 | 15 |

| 128 | LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk. *British Journal of Cancer*, **2014**, 110, 2123-30 | 8.7 | 16 |

| 127 | Next-generation sequencing of urologic cancers: next is now. *European Urology*, **2014**, 66, 4-7 | 10.2 | 7 |

| 126 | Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis. *PLoS ONE*, **2014**, 9, e89952 | 3.7 | 13 |

| 125 | Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. *PLoS ONE*, **2014**, 9, e96849 | 3.7 | 34 |

| 124 | Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A. *Carcinogenesis*, **2014**, 35, 2670-8 | 4.6 | 37 |

| 123 | Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Human Molecular Genetics*, **2014**, 23, 6616-33 | 5.6 | 77 |

| 122 | LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk. *Epigenetics*, **2014**, 9, 1532-9 | 5.7 | 21 |

121	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. *European Urology*, **2014**, 65, 360-6	10.2	166
120	Biological and statistical approaches for modeling exposure to specific trihalomethanes and bladder cancer risk. *American Journal of Epidemiology*, **2013**, 178, 652-60	3.8	16
119	Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. *Cancer Research*, **2013**, 73, 2211-20	10.1	82
118	Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. *Nature Genetics*, **2013**, 45, 1464-9	36.3	186
117	Genome-wide association study identifies two susceptibility loci for osteosarcoma. *Nature Genetics*, **2013**, 45, 799-803	36.3	156
116	Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach. *Journal of Chromatography A*, **2013**, 1318, 163-70	4.5	91
115	Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA. *Environmental Health Perspectives*, **2013**, 121, 650-6	8.4	66
114	Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. *PLoS Medicine*, **2013**, 10, e1001380	16.06	382
113	Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 803-11	4	67
112	Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. *Public Health Genomics*, **2013**, 16, 159-73	1.9	7
111	EU Pancreas: an integrated European platform for pancreas cancer research--from basic science to clinical and public health interventions for a rare disease. *Public Health Genomics*, **2013**, 16, 305-12	1.9	1
110	Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. *International Journal of Cancer*, **2013**, 133, 597-603	7.5	18
109	ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. *PLoS ONE*, **2013**, 8, e62483	3.7	41
108	An epistatic interaction between the PAX8 and STK17B genes in papillary thyroid cancer susceptibility. *PLoS ONE*, **2013**, 8, e74765	3.7	8
107	Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. *PLoS ONE*, **2013**, 8, e83745	3.7	12
106	Advantage of using allele-specific copy numbers when testing for association in regions with common copy number variants. *PLoS ONE*, **2013**, 8, e75350	3.7	5
105	Genome-wide CNV analysis replicates the association between GSTM1 deletion and bladder cancer: a support for using continuous measurement from SNP-array data. *BMC Genomics*, **2012**, 13, 326	4.5	14
104	Public health perspective: from personalized medicine to personal health. *Personalized Medicine*, **2012**, 9, 115-119	2.2	13

103	A dynamic model for the risk of bladder cancer progression. *Statistics in Medicine*, **2012**, 31, 287-300	2.3	6
102	Detectable clonal mosaicism and its relationship to aging and cancer. *Nature Genetics*, **2012**, 44, 651-8	36.3	409
101	Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. *Human Molecular Genetics*, **2012**, 21, 1918-30	5.6	58
100	Pancreatic cancer risk and levels of trace elements. *Gut*, **2012**, 61, 1583-8	19.2	68
99	Relationships of hepatic and pancreatic biomarkers with the cholestatic syndrome and tumor stage in pancreatic cancer. *Biomarkers*, **2012**, 17, 557-65	2.6	6
98	Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. *British Journal of Cancer*, **2012**, 107, 1392-8	8.7	27
97	Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 4974-9	11.5	69
96	Public health genomics in Spain: the status of a non-existing reality. *Public Health Genomics*, **2012**, 15, 313-21	1.9	
95	Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. *Journal of the National Cancer Institute*, **2012**, 104, 1897-904	9.7	28
94	Select your SNPs (SYSNPs): a web tool for automatic and massive selection of SNPs. *International Journal of Data Mining and Bioinformatics*, **2012**, 6, 324-34	0.5	19
93	Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. *PLoS ONE*, **2012**, 7, e29396	3.7	33
92	Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. *PLoS ONE*, **2012**, 7, e45025	3.7	20
91	An unusual suspect: an uncommon human-specific synonymous coding variant within the UGT1A6 gene explains a GWAS signal and protects against bladder cancer. *Genome Biology*, **2011**, 12,	18.3	78
90	AUC-RF: a new strategy for genomic profiling with random forest. *Human Heredity*, **2011**, 72, 121-32	1.1	85
89	Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. *European Journal of Epidemiology*, **2011**, 26, 229-36	12.1	12
88	Socioeconomic status and exposure to disinfection by-products in drinking water in Spain. *Environmental Health*, **2011**, 10, 18	6	16
87	Assessment of copy number variation using the Illumina Infinium 1M SNP-array: a comparison of methodological approaches in the Spanish Bladder Cancer/EPICURO study. *Human Mutation*, **2011**, 32, 240-8	4.7	49
86	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2222-31	4	27

85	Public health genomics and the challenges for epidemiology. *European Journal of Public Health*, **2011**, 21, 5-6	2.1	1
84	Urinary pH, cigarette smoking and bladder cancer risk. *Carcinogenesis*, **2011**, 32, 843-7	4.6	28
83	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. *Journal of Medical Genetics*, **2011**, 48, 698-702	5.8	5
82	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. *Human Molecular Genetics*, **2011**, 20, 4282-9	5.6	82
81	A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. *Pharmacogenetics and Genomics*, **2011**, 21, 231-6	1.9	44
80	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nature Genetics*, **2010**, 42, 978-84	36.3	408
79	Selenium and bladder cancer risk: a meta-analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2407-15	4	78
78	Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. *Cancer Prevention Research*, **2010**, 3, 1235-45	3.2	42
77	Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 20780-5	11.5	71
76	mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. *Bioinformatics*, **2010**, 26, 2198-9	7.2	73
75	Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. *Environmental Health Perspectives*, **2010**, 118, 1545-50	8.4	162
74	Statistical consideration for clinical biomarker research in bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 389-400	2.8	99
73	The relative influence of diet and serum concentrations of organochlorine compounds on K-ras mutations in exocrine pancreatic cancer. *Chemosphere*, **2010**, 79, 686-97	8.4	15
72	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. *Breast Cancer Research*, **2010**, 12, R110	8.3	74
71	Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. *American Journal of Human Genetics*, **2010**, 87, 129-38	11	100
70	Genetic susceptibility to distinct bladder cancer subphenotypes. *European Urology*, **2010**, 57, 283-92	10.2	52
69	Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. *Cancer Research*, **2009**, 69, 6857-64	10.1	94
68	In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations. *Mutagenesis*, **2009**, 24, 513-21	2.8	14

67	Determinants of quality of interview and impact on risk estimates in a case-control study of bladder cancer. *American Journal of Epidemiology*, **2009**, 170, 237-43	3.8	8
66	Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. *European Urology*, **2009**, 55, 658	10.2	
65	TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. *International Journal of Cancer*, **2009**, 124, 608-13	7.5	41
64	Lifetime history of alcohol consumption and K-ras mutations in pancreatic ductal adenocarcinoma. *Environmental and Molecular Mutagenesis*, **2009**, 50, 421-30	3.2	9
63	Coffee consumption, genetic susceptibility and bladder cancer risk. *Cancer Causes and Control*, **2009**, 20, 121-7	2.8	32
62	Bladder cancer and reproductive factors among women in Spain. *Cancer Causes and Control*, **2009**, 20, 1907-13	2.8	13
61	Correcting serum concentrations of organochlorine compounds by lipids: alternatives to the organochlorine/total lipids ratio. *Environment International*, **2009**, 35, 1080-5	12.9	32
60	Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. *Mutation Research - Reviews in Mutation Research*, **2009**, 682, 83-93	7	63
59	The inherited genetic component of sporadic pancreatic adenocarcinoma. *Pancreatology*, **2009**, 9, 206-14	3.8	8
58	Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. *Lancet Oncology, The*, **2008**, 9, 359-66	21.7	193
57	Caffeic acid phenethyl ester induces apoptosis of human pancreatic cancer cells involving caspase and mitochondrial dysfunction. *Pancreatology*, **2008**, 8, 566-76	3.8	50
56	Genetic epidemiology of bladder cancer: scaling up in the identification of low-penetrance genetic markers of bladder cancer risk and progression. *Scandinavian Journal of Urology and Nephrology*, **2008**, 131-40		12
55	Air pollution and risk of urinary bladder cancer in a case-control study in Spain. *Occupational and Environmental Medicine*, **2008**, 65, 56-60	2.1	51
54	Occupation and bladder cancer in a hospital-based case-control study in Spain. *Occupational and Environmental Medicine*, **2008**, 65, 347-53	2.1	48
53	Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. *Carcinogenesis*, **2008**, 29, 1955-62	4.6	76
52	CYP1B1 polymorphisms and k-ras mutations in patients with pancreatic ductal adenocarcinoma. *Digestive Diseases and Sciences*, **2008**, 53, 1417-21	4	8
51	Screening for bladder cancer: a perspective. *World Journal of Urology*, **2008**, 26, 13-8	4	35
50	Improving strategies for detecting genetic patterns of disease susceptibility in association studies. *Statistics in Medicine*, **2008**, 27, 6532-46	2.3	74

49	Does increased urination frequency protect against bladder cancer?. *International Journal of Cancer*, **2008**, 123, 1644-8	7.5	25
48	Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer. *Environmental Health Perspectives*, **2007**, 115, 1569-72	8.4	53
47	Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. *International Journal of Cancer*, **2007**, 120, 2452-8	7.5	53
46	Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. *Clinical Cancer Research*, **2007**, 13, 3545-51	12.9	164
45	Epidemiology of urinary bladder cancer: from tumor development to patient's death. *World Journal of Urology*, **2007**, 25, 285-95	4	203
44	Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. *European Journal of Epidemiology*, **2007**, 22, 577-88	12.1	23
43	Genetic variation in the base excision repair pathway and bladder cancer risk. *Human Genetics*, **2007**, 121, 233-42	6.3	107
42	Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. *PLoS Genetics*, **2007**, 3, e29	6	109
41	Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. *Carcinogenesis*, **2007**, 28, 1788-93	4.6	83
40	Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 1595-600	4	70
39	Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer. *Journal of Epidemiology and Community Health*, **2007**, 61, 641-9	5.1	22
38	Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. *International Journal of Epidemiology*, **2007**, 36, 236-41	7.8	31
37	Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer. *Pancreas*, **2007**, 35, 135-41	2.6	22
36	Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. *European Journal of Cancer*, **2007**, 43, 1731-40	7.5	99
35	The influence of lipid and lifestyle factors upon correlations between highly prevalent organochlorine compounds in patients with exocrine pancreatic cancer. *Environment International*, **2007**, 33, 946-54	12.9	18
34	Bladder cancer and apoptosis: matters of life and death. *Lancet Oncology, The*, **2007**, 8, 91-2	21.7	5
33	Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. *American Journal of Epidemiology*, **2007**, 165, 148-56	3.8	382
32	Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1348-54	4	121

31	PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. *Cancer Research*, **2006**, 66, 7401-4	10.1	175
30	The p53 pathway and outcome among patients with T1G3 bladder tumors. *Clinical Cancer Research*, **2006**, 12, 6029-36	12.9	53
29	Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. *Journal of Clinical Oncology*, **2006**, 24, 3664-71	2.2	256
28	Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 536-42	4	128
27	Assessment of lifetime exposure to trihalomethanes through different routes. *Occupational and Environmental Medicine*, **2006**, 63, 273-7	2.1	47
26	Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1696-702	4	41
25	Estimating dietary intakes from a brief questionnaire: A simulation study of reliability in a molecular epidemiologic study of pancreatic and biliary diseases. *European Journal of Epidemiology*, **2006**, 21, 417-26	12.1	9
24	NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. *Lancet, The*, **2005**, 366, 649-59	40	483
23	P53 as a prognostic marker for bladder cancer: a meta-analysis and review. *Lancet Oncology, The*, **2005**, 6, 678-86	21.7	244
22	Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. *Clinical and Translational Oncology*, **2005**, 7, 189-97	3.6	179
21	FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. *Clinical Cancer Research*, **2005**, 11, 5444-50	12.9	106
20	The International Bladder Cancer Bank: proposal for a new study concept. *Urologic Oncology: Seminars and Original Investigations*, **2004**, 22, 277-84	2.8	17
19	Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. *European Urology*, **2003**, 43, 53-62	10.2	42
18	Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. *International Journal of Cancer*, **2003**, 107, 635-41	7.5	47
17	Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. *Gut*, **2002**, 50, 653-7	19.2	26
16	Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. *Carcinogenesis*, **2002**, 23, 101-6	4.6	40
15	Generalizing molecular results arising from incomplete biological samples: expected bias and unexpected findings. *Annals of Epidemiology*, **2002**, 12, 7-14	6.4	11
14	Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group. *Gut*, **2001**, 48, 70-4	19.2	86

13	Gene-environment interactions in pancreatic cancer. *Pancreatology*, **2001**, 1, 472-6	3.8	20
12	Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group. *European Journal of Epidemiology*, **2000**, 16, 533-41	12.1	31
11	Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda. *Journal of Epidemiology and Community Health*, **2000**, 54, 656-9	5.1	17
10	Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. *Journal of Epidemiology and Community Health*, **1999**, 53, 702-9	5.1	50
9	Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. PANKRAS II Study Group. *Digestive Diseases and Sciences*, **1999**, 44, 2469-77	4	23
8	Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. *Lancet, The*, **1999**, 354, 2125-9	40	146
7	Review of studies of selected metabolic polymorphisms and cancer. *Iarc (international Agency for Research on Cancer) Scientific Publications*, **1999**, 323-93		15
6	Learning from case reports: diagnostic issues in an epidemiologic study of pancreatic cancer. *Journal of Clinical Epidemiology*, **1998**, 51, 1215-21	5.7	17
5	Occurrence, trends and environment etiology of pancreatic cancer. *Scandinavian Journal of Work, Environment and Health*, **1998**, 24, 165-74	4.3	77
4	Ki-ras mutations in exocrine pancreatic cancer: association with clinico-pathological characteristics and with tobacco and alcohol consumption. PANK-ras I Project Investigators. *International Journal of Cancer*, **1997**, 70, 661-7	7.5	58
3	Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer's judgement. *European Journal of Epidemiology*, **1996**, 12, 553-62	12.1	15
2	Diagnostic certainty and potential for misclassification in exocrine pancreatic cancer. PANKRAS I Project Investigations. *Journal of Clinical Epidemiology*, **1994**, 47, 1069-79	5.7	20
1	An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer		1